Utility of 10 Immunohistochemical Markers Including Novel Markers (Desmocollin-3, Glypican 3, S100A2, S100A7, and Sox-2) for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung
Authors:
- 1 July 2011
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 6 (7) , 1190-1199
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Subclassification of Non-small Cell Lung Carcinomas Lacking Morphologic Differentiation on Biopsy SpecimensAmerican Journal of Surgical Pathology, 2011
- Optimal Immunohistochemical Markers For Distinguishing Lung Adenocarcinomas From Squamous Cell Carcinomas in Small Tumor SamplesAmerican Journal of Surgical Pathology, 2010
- Subtyping of Undifferentiated Non-small Cell Carcinomas in Bronchial Biopsy SpecimensJournal of Thoracic Oncology, 2010
- Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation AnalysisJournal of Thoracic Oncology, 2010
- Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non—Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized TreatmentsInternational Journal of Surgical Pathology, 2009
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- TTF-1, Cytokeratin 7, 34βE12, and CD56/NCAM Immunostaining in the Subclassification of Large Cell Carcinomas of the LungAmerican Journal of Clinical Pathology, 2004
- Value of p63 and Cytokeratin 5/6 as Immunohistochemical Markers for the Differential Diagnosis of Poorly Differentiated and Undifferentiated CarcinomasAmerican Journal of Clinical Pathology, 2001
- Thyroid transcription factor‐1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and BHistopathology, 2000